Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

BrettonWoodsW Dec. 25 at 10:22 AM

$ALDX Expectations reset as evidence replaces narrative, as investors weigh durability over pace. Proof points carry more weight than guidance alone.

0 · Reply

United2001 Dec. 25 at 2:26 AM

$ALDX Merry Christmas everyone!! Feliz Navidad a todos! Frohe Weihnachten euch allen! Glædelig jul allesammen!

0 · Reply

MoneyGroupLLC Dec. 24 at 8:48 PM

Enter: $ALDX Calls Strike Price: $6 Expiry Date: JAN 16 2026 Buy in Price: $0.26 - $0.27 Sell Price: $0.45 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

GoldmanSlaps Dec. 24 at 8:10 PM

$ALDX someone been randomly buying 20k shares late in after hours the past couple days 🤔

1 · Reply

ParabolicalSpartan Dec. 24 at 3:17 PM

What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems Swings: $ALDX $CYN $NWBO $MMTLP d

1 · Reply

TheSideHustler Dec. 24 at 10:16 AM

$ALDX Investor conviction will hinge on whether resource allocation supports scalability without eroding optionality. Sustained traction would support a meaningful re-rating.

0 · Reply

Moneymachineuser Dec. 23 at 7:57 PM

$ALDX amazing!!

2 · Reply

PeterV9764 Dec. 23 at 6:14 PM

$ALDX Here’s hoping the FDA gets its act together and fixes this in Jan or Feb!! Happy Holidays all!

0 · Reply

AllinDeyra Dec. 23 at 5:23 PM

$ALDX approval 8-12, Abbvie Option 10-16 USD

0 · Reply

AllinDeyra Dec. 23 at 5:22 PM

$ALDX normal fluctuation in the way to 7-8 USD before March 2026

0 · Reply

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Dec 15, 2025, 7:30 PM EST - 9 days ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Nov 13, 2025, 3:11 PM EST - 5 weeks ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Nov 13, 2025, 7:00 AM EST - 6 weeks ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 6 weeks ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 7 weeks ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Oct 28, 2025, 7:01 AM EDT - 2 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 10, 2025, 4:32 AM EDT - 2 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Sep 3, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 5 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 6 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 8 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 8 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 8 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 8 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 8 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 8 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 8 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 8 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 8 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 8 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 8 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 8 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 8 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 8 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 8 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 8 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 7:36 AM EDT - 8 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 24, 2025, 3:18 PM EDT - 8 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 8 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 8 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 22, 2025, 3:23 PM EDT - 8 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 21, 2025, 10:52 AM EDT - 8 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 8:33 AM EDT - 8 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

Apr 18, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation

BrettonWoodsW Dec. 25 at 10:22 AM

$ALDX Expectations reset as evidence replaces narrative, as investors weigh durability over pace. Proof points carry more weight than guidance alone.

0 · Reply

United2001 Dec. 25 at 2:26 AM

$ALDX Merry Christmas everyone!! Feliz Navidad a todos! Frohe Weihnachten euch allen! Glædelig jul allesammen!

0 · Reply

MoneyGroupLLC Dec. 24 at 8:48 PM

0 · Reply

GoldmanSlaps Dec. 24 at 8:10 PM

$ALDX someone been randomly buying 20k shares late in after hours the past couple days 🤔

1 · Reply

ParabolicalSpartan Dec. 24 at 3:17 PM

What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems Swings: $ALDX $CYN $NWBO $MMTLP d

1 · Reply

TheSideHustler Dec. 24 at 10:16 AM

$ALDX Investor conviction will hinge on whether resource allocation supports scalability without eroding optionality. Sustained traction would support a meaningful re-rating.

0 · Reply

Moneymachineuser Dec. 23 at 7:57 PM

$ALDX amazing!!

2 · Reply

PeterV9764 Dec. 23 at 6:14 PM

$ALDX Here’s hoping the FDA gets its act together and fixes this in Jan or Feb!! Happy Holidays all!

0 · Reply

AllinDeyra Dec. 23 at 5:23 PM

$ALDX approval 8-12, Abbvie Option 10-16 USD

0 · Reply

AllinDeyra Dec. 23 at 5:22 PM

$ALDX normal fluctuation in the way to 7-8 USD before March 2026

0 · Reply

Catmando3 Dec. 23 at 5:07 PM

$ALDX me today

0 · Reply

alwaysgood2know Dec. 23 at 4:48 PM

$ALDX still and very!

0 · Reply

All4Retiring Dec. 23 at 4:14 PM

$ALDX Merry Christmas and Happy New Year everyone. Looking forward to a great 2026.

1 · Reply

TripleGateCptl Dec. 23 at 3:53 PM

$ALDX Come on guys! This feels very disappointing. They got the label, what can possibly go wrong from here?! Why isn’t this stock going straight up!!

1 · Reply

OfficialStocktwitsUser Dec. 23 at 4:23 AM

$ALDX RSI: 59.18, MACD: 0.0069 Vol: 0.39, MA20: 4.99, MA50: 5.07 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MoneyGroupLLC Dec. 23 at 3:04 AM

Enter: $ALDX Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.45 - $0.60 Sell Price: $0.87 Profit : +94% (Turn every $1 into $1.94) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MUBSN Dec. 22 at 9:56 PM

$ALDX market realising that the approval is done! I think we will see double digits in few days, the uptrend will continue

1 · Reply

AMSNL Dec. 22 at 8:40 PM

$ALDX carry on we've been here before

0 · Reply

FullPorrtDipz Dec. 22 at 7:24 PM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Big block buys on $POET $BKSY $RGTI $ALDX

0 · Reply

jacdan1018 Dec. 22 at 6:29 PM

$ALDX interesting that the stock pops the day after the Dec options expired. Either way, let’s go baby!

1 · Reply

RoyBasch Dec. 22 at 5:40 PM

$ALDX 2026 is gonna be the year

1 · Reply

GoldmanSlaps Dec. 22 at 4:33 PM

$ALDX

1 · Reply

Market Cap	303.82M
Revenue (ttm)	0.00
Net Income (ttm)	-55.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	419,900
Avg Vol	1,063,066
Day's Range	N/A - N/A
Shares Out	60.16M
Stochastic %K	74%
Beta	0.83
Analysts	Strong Sell
Price Target	$9.00